Answers to the antiphospholipid-antibody syndrome?

M. Lockshin

DOI: https://doi.org/10.1056/NEJM199504133321510

IF: 158.5

1995-04-13

New England Journal of Medicine

Abstract:Truly elegant clinical science defines syndromes with precision, delineates pathogenic mechanisms, and compares treatments in prospective randomized trials. Conventional clinical science lacks prec...

What problem does this paper attempt to address?

Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis

Toshiki Kuno,Atsuyuki Watanabe,Satoshi Shoji,Tomohiro Fujisaki,Hiroki Ueyama,Hisato Takagi,Pierre Deharo,Thomas Cuisset,Sripal Bangalore,Roxana Mehran,Gregg W Stone,Shun Kohsaka,Deepak L Bhatt

DOI: https://doi.org/10.1161/CIRCINTERVENTIONS.123.013242

Abstract:Background: Short-term (≤6 months) dual antiplatelet therapy (DAPT) and DAPT de-escalation become attractive for patients with acute coronary syndrome. Methods: A systemic search identified randomized controlled trials that included patients with acute coronary syndrome treated using (1) standard DAPT (12 months) with clopidogrel, prasugrel (standard/low dose), or ticagrelor; (2) extended DAPT (≥18 months); (3) short-term DAPT (≤6 months) followed by P2Y12 inhibitor or aspirin; (4) 12-month DAPT with unguided de-escalation from potent P2Y12 inhibitors to low-dose potent P2Y12 inhibitor or clopidogrel at 1 month; and (5) guided selection DAPT with genotype or platelet function tests. The primary efficacy outcome (major adverse cardiovascular events) was a composite of cardiovascular death, myocardial infarction, or stroke. The primary safety outcome was major or minor bleeding. Results: This meta-analysis included 32 randomized controlled trials with 103 497 patients. While there were no differences in efficacy between short, unguided de-escalation and guided selection strategies, unguided de-escalation was associated with reduced risk of major adverse cardiovascular events compared with standard DAPT with clopidogrel or ticagrelor (hazard ratio [95% CI], 0.67 [0.49-0.93] and 0.68 [0.50-0.93]). Both short DAPT followed by P2Y12 inhibitor and unguided de-escalation were associated with reduced risks in safety compared with other strategies, including guided selection (hazard ratio [95% CI], 0.66 [0.47-0.93] and 0.48 [0.33-0.71]). Short DAPT followed by a P2Y12 inhibitor was associated with reduced risk of major bleeding and all-cause death compared with standard, extended DAPT (eg, versus DAPT with clopidogrel; hazard ratio [95% CI], 0.64 [0.42-0.97] and 0.60 [0.44-0.82]). By rankogram, unguided de-escalation strategy was the safest and most effective strategy in reducing major adverse cardiovascular events and major or minor bleeding while short DAPT followed by P2Y12 inhibitor was ranked the best for major bleeding and all-cause death. Conclusions: In patients with acute coronary syndrome, unguided de-escalation was associated with the lowest risk of major adverse cardiovascular events and major or minor bleeding outcomes, while short DAPT followed by P2Y12 inhibitor was associated with the lowest risk of major bleeding and all-cause death.
Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis

Pedro E P Carvalho,Douglas M Gewehr,Bruno R Nascimento,Lara Melo,Giullia Burkhardt,André Rivera,Marcelo A P Braga,Patricia O Guimarães,Roxana Mehran,Stephan Windecker,Marco Valgimigli,Dominick J Angiolillo,Deepak L Bhatt,Yader Sandoval,Shao-Liang Chen,Gregg W Stone,Renato D Lopes

DOI: https://doi.org/10.1001/jamacardio.2024.3216

2024-10-09

Abstract:Importance: The optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) remains under debate. Objectives: To analyze the efficacy and safety of DAPT strategies in patients with ACS using a bayesian network meta-analysis. Data sources: MEDLINE, Embase, Cochrane, and LILACS databases were searched from inception to April 8, 2024. Study selection: Randomized clinical trials (RCTs) comparing DAPT duration strategies in patients with ACS undergoing PCI were selected. Short-term strategies (1 month of DAPT followed by P2Y12 inhibitors, 3 months of DAPT followed by P2Y12 inhibitors, 3 months of DAPT followed by aspirin, and 6 months of DAPT followed by aspirin) were compared with conventional 12 months of DAPT. Data extraction and synthesis: This systematic review and network meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The risk ratio (RR) with a 95% credible interval (CrI) was calculated within a bayesian random-effects network meta-analysis. Treatments were ranked using surface under the cumulative ranking (SUCRA). Main outcomes and measures: The primary efficacy end point was major adverse cardiac and cerebrovascular events (MACCE); the primary safety end point was major bleeding. Results: A total of 15 RCTs randomizing 35 326 patients (mean [SD] age, 63.1 [11.1] years; 26 954 male [76.3%]; 11 339 STEMI [32.1%]) with ACS were included. A total of 24 797 patients (70.2%) received potent P2Y12 inhibitors (ticagrelor or prasugrel). Compared with 12 months of DAPT, 1 month of DAPT followed by P2Y12 inhibitors reduced major bleeding (RR, 0.47; 95% CrI, 0.26-0.74) with no difference in MACCE (RR, 1.00; 95% CrI, 0.70-1.41). No significant differences were observed in MACCE incidence between strategies, although CrIs were wide. SUCRA ranked 1 month of DAPT followed by P2Y12 inhibitors as the best for reducing major bleeding and 3 months of DAPT followed by P2Y12 inhibitors as optimal for reducing MACCE (RR, 0.85; 95% CrI, 0.56-1.21). Conclusion and relevance: Results of this systematic review and network meta-analysis reveal that, in patients with ACS undergoing PCI with DES, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE when compared with 12 months of DAPT. However, an increased risk of MACCE cannot be excluded, and 3 months of DAPT followed by potent P2Y12 inhibitor monotherapy was ranked as the best option to reduce MACCE. Because most patients receiving P2Y12 inhibitor monotherapy were taking ticagrelor, the safety of stopping aspirin in those taking clopidogrel remains unclear.
Comparing dual antiplatelet therapy strategies post-acute coronary syndrome: network meta-analysis

R Turgeon,C Hong,E H Z Wang,G C Wong,U Ellis

DOI: https://doi.org/10.1093/eurheartj/ehac544.2716

IF: 39.3

2022-10-18

European Heart Journal

Abstract:Background Various approaches to dual antiplatelet therapy (DAPT) management exist to balance thrombotic and bleeding risks following acute coronary syndrome (ACS). Purpose The aim of this study was to compare and rank different DAPT management strategies in patients with ACS with or without percutaneous coronary interventions. Methods We conducted a systematic review with network meta-analysis of randomized controlled trials comparing DAPT strategies in patients with ACS using MEDLINE, Embase, and CENTRAL (2007-July 2021). The primary outcome was major adverse cardiovascular events (MACE). Secondary outcomes included all-cause death and major bleeding. We performed Bayesian network meta-analyses to compare all interventions simultaneously using the Markov-chain Monte Carlo method, conducted under the assumption of transitivity. We generated odds ratios (ORs) with 95% credible intervals (CrI) from the medians and 2.5th and 97.5th percentiles of the posterior distributions using a hierarchical Bayesian framework, using a random-effects model with informative priors for between-study heterogeneity based on pharmacological interventions with semi-objective outcomes (MACE or bleeding) or death. To rank interventions for each outcome, we calculated the mean surface under the cumulative ranking (SUCRA) curve. Results From 5941 articles, we included 24 trials (89,620 patients). Both clopidogrel- and ticagrelor-based DAPT increased MACE compared with pharmacogenomics-guided P2Y12 inhibitor selection (odds ratio [OR] 1.37, 95% credible interval [CrI] 1.08–1.74 and 1.35, 1.05–1.79, respectively) and empiric P2Y12 inhibitor de-escalation (OR 1.53, 95%CrI 1.00–2.30 and 1.51, 1.00–2.27, respectively). Compared with short-duration DAPT, standard DAPT duration with all P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) and pharmacogenomics-guided P2Y12 inhibitor selection increased major bleeding. Ticagrelor-based DAPT increased major bleeding compared with platelet function testing-guided DAPT (OR 1.60, 95%CrI 1.00–2.55). Empiric P2Y12 inhibitor de-escalation ranked best for MACE (SUCRA 0.89), whereas short-duration DAPT ranked best for death (SUCRA 0.89) and major bleeding (SUCRA 0.93). Conclusions In patients with ACS, empiric P2Y12 inhibitor de-escalation was most efficacious whereas short-duration DAPT was the safest compared to other DAPT strategies. Funding Acknowledgement Type of funding sources: None.

cardiac & cardiovascular systems
Comparison of Unguided De-Escalation Versus Guided Selection of Dual Antiplatelet Therapy After Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis

Toshiki KunoTomohiro FujisakiSatoshi ShojiYuki SahashiYusuke TsugawaMasao IwagamiHisato TakagiAlexandros BriasoulisPierre DeharoThomas CuissetAzeem LatibShun KohsakaDeepak L. BhattDivision of Cardiology,Montefiore Medical Center,Albert Einstein College of Medicine,New York,NY (T.K.,A.L.).Department of Medicine,Icahn School of Medicine at Mount Sinai,Mount Sinai Beth Israel,New York,NY (T.K.).Department of Cardiovascular Medicine,Graduate School of Medical Sciences,Kumamoto University,Japan (T.F.).Department of Medicine,Icahn School of Medicine at Mount Sinai,Mount Sinai Morningside and West,New York,NY (T.F.).Department of Cardiology,Keio University School of Medicine,Tokyo,Japan (S.S.,S.K.).Department of Cardiology,Gifu University,Japan (Y.S.).Division of General Internal Medicine and Health Services Research,David Geffen School of Medicine at UCLA,Los Angeles,CA (Y.T.).Department of Health Policy and Management,UCLA Fielding School of Public Health,Los Angeles,CA (Y.T.).Department of Health Services Research,University of Tsukuba,Japan (M.I.).Department of Cardiovascular Surgery,Shizuoka Medical Center,Japan (H.T.).Division of Cardiology,Heart Failure and Transplantation,University of Iowa' Iowa City (A.B.).Département de Cardiologie,CHU Timone,Marseille,France (P.D.,T.C.).Center for Cardiovascular and Nutrition Research,INSERM,INRA (P.D.,T.C.),Aix-Marseille Université,France.Faculté de Médecine (P.D.,T.C.),Aix-Marseille Université,France.Brigham and Women's Hospital Heart and Vascular Center,Harvard Medical School,Boston,MA (D.L.B.).

DOI: https://doi.org/10.1161/CIRCINTERVENTIONS.122.011990

2022-07-28

Abstract:The benefit of dual antiplatelet therapy (DAPT) for reducing ischemic events is greatest in the early period of acute coronary syndrome, and recent randomized controlled trials have investigated the unguided de-escalation strategy of changing potent P2Y 12 inhibitors to less potent or reduced-dose P2Y 12 inhibitors 1 month after acute coronary syndrome. However, it remains unclear which strategy is more effective and safer: the uniform unguided de-escalation strategy versus the personalized guided selection of DAPT with genotype or platelet function tests. PubMed, EMBASE, and Cochrane Central were searched for articles published from database inception to September 10, 2021. Randomized controlled trials investigating DAPT using clopidogrel, low-dose prasugrel, standard-dose prasugrel, ticagrelor, unguided de-escalation strategy, and guided selection strategy for patients with acute coronary syndrome were included. Hazard ratios and relative risk estimates were extracted from each study. The estimates were pooled using a random-effects network meta-analysis. The primary efficacy outcome was major adverse cardiovascular events, defined as a composite of cardiovascular death, myocardial infarction, or stroke. The primary safety outcome was major or minor bleeding. Secondary outcomes were all-cause death, cardiovascular death, myocardial infarction, stroke, stent thrombosis, and major bleeding. This study included 19 randomized controlled trials with 69 746 patients. Compared with guided selection of DAPT, unguided de-escalation of DAPT was associated with a decreased risk of the primary safety outcome (hazard ratio, 0.48 [95% CI, 0.33–0.72]) without increased risks of major adverse cardiovascular events (hazard ratio, 0.82 [95% CI, 0.53–1.28]) or any secondary outcomes. The results were similar when the guided selection strategy was divided into platelet function–guided and genotype-guided strategies. Compared with guided selection of DAPT, unguided de-escalation of DAPT decreased bleeding without increasing ischemic events in patients after acute coronary syndrome. If a strategy of de-escalation is chosen, these findings do not support the routine use of personalized guiding tests. URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42021273082. Download figure Download PowerPoint
SHORT-TERM DUAL ANTIPLATELET THERAPY AFTER DRUG-ELUTING STENTING IN PATIENTS WITH ACUTE CORONARY SYNDROMES: A BAYESIAN NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Pedro E. P. Carvalho,Douglas M. Gewehr,Bruno R. Nascimento,Lara Melo,Giullia Burkhardt,Andre Rivera,Marcelo A. P. Braga,Patricia O. Guimaraes,Roxana Mehran,Stephan Windecker,Marco Valgimigli,Dominick J. Angiolillo,Deepak L. Bhatt,Yader Sandoval,Shao-Liang Chen,Gregg W. Stone,Renato D. Lopes

DOI: https://doi.org/10.1001/jamacardio.2024.3216

2024-01-01

JAMA Cardiology

Abstract:ImportanceThe optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) remains under debate.ObjectivesTo analyze the efficacy and safety of DAPT strategies in patients with ACS using a bayesian network meta-analysis.Data SourcesMEDLINE, Embase, Cochrane, and LILACS databases were searched from inception to April 8, 2024.Study SelectionRandomized clinical trials (RCTs) comparing DAPT duration strategies in patients with ACS undergoing PCI were selected. Short-term strategies (1 month of DAPT followed by P2Y12 inhibitors, 3 months of DAPT followed by P2Y12 inhibitors, 3 months of DAPT followed by aspirin, and 6 months of DAPT followed by aspirin) were compared with conventional 12 months of DAPT.Data Extraction and SynthesisThis systematic review and network meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The risk ratio (RR) with a 95% credible interval (CrI) was calculated within a bayesian random-effects network meta-analysis. Treatments were ranked using surface under the cumulative ranking (SUCRA).Main Outcomes and MeasuresThe primary efficacy end point was major adverse cardiac and cerebrovascular events (MACCE); the primary safety end point was major bleeding.ResultsA total of 15 RCTs randomizing 35 326 patients (mean [SD] age, 63.1 [11.1] years; 26 954 male [76.3%]; 11 339 STEMI [32.1%]) with ACS were included. A total of 24 797 patients (70.2%) received potent P2Y12 inhibitors (ticagrelor or prasugrel). Compared with 12 months of DAPT, 1 month of DAPT followed by P2Y12 inhibitors reduced major bleeding (RR, 0.47; 95% CrI, 0.26-0.74) with no difference in MACCE (RR, 1.00; 95% CrI, 0.70-1.41). No significant differences were observed in MACCE incidence between strategies, although CrIs were wide. SUCRA ranked 1 month of DAPT followed by P2Y12 inhibitors as the best for reducing major bleeding and 3 months of DAPT followed by P2Y12 inhibitors as optimal for reducing MACCE (RR, 0.85; 95% CrI, 0.56-1.21).Conclusion and RelevanceResults of this systematic review and network meta-analysis reveal that, in patients with ACS undergoing PCI with DES, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE when compared with 12 months of DAPT. However, an increased risk of MACCE cannot be excluded, and 3 months of DAPT followed by potent P2Y12 inhibitor monotherapy was ranked as the best option to reduce MACCE. Because most patients receiving P2Y12 inhibitor monotherapy were taking ticagrelor, the safety of stopping aspirin in those taking clopidogrel remains unclear.
Acute lymphocytic leukemia presenting as masquerade syndrome.

S. Dadeya,K. Malik,B. P. Guliani,S. Dewan,R. Mehta,V. Gupta

DOI: https://doi.org/10.3928/1542-8877-20020301-17

2002-03-01

Abstract:An 11-year-old child presented with plastic iridocyclitis and hypopyon. Subsequent paracentesis revealed leukemic infiltrates. A bone marrow biopsy confirmed the diagnosis of acute lymphocytic leukemia. Because of this unusual case of leukemic hypopyon, we advocate anterior chamber paracentesis and pediatrician referral in all cases of refractory uveitis.
Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis

Waqas Ullah,Harigopal Sandhyavenu,Amro Taha,Smitha Narayana Gowda,Maryam Mukhtar,Aravind Reddy Polam,Salman Zahid,David L Fischman,Michael P Savage,Sunil V Rao,Mohamad Alkhouli

DOI: https://doi.org/10.1161/JAHA.122.032490

2024-10-11

Abstract:Background: Optimal duration and choice of antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention remain controversial. Methods and results: Digital databases (PubMed, Cochrane, and Embase) were queried to select all randomized controlled trials on a post-percutaneous coronary intervention population with acute coronary syndrome. Dual-antiplatelet therapy (DAPT) with aspirin and clopidogrel for 12 months was compared with 4 major strategies: high-potency, high- to low-potency, low-dose, and short-duration DAPT. A network meta-analysis was performed to compare the safety and efficacy of different antiplatelet strategies. This study was the second updated manuscript under the International Prospective Register of Systematic Review registration (CRD42021286552). Thirty-two randomized controlled trials comprising 103 459 (51 750 experimental, 51 709 control) patients were included. Compared with DAPT with aspirin and clopidogrel for 12 months, high- to low-potency DAPT (risk ratio [RR], 0.69 [95% CI, 0.52-0.92]) and aspirin+prasugrel containing DAPT for 12 months (RR, 0.84 [95% CI, 0.72-0.98]) had a significantly lower, whereas DAPT for 1 month followed by clopidogrel only (RR, 1.59 [95% CI, 1.06-2.39]) had a higher, incidence of major adverse cardiovascular events at 1 year (median follow-up). Prasugrel (RR, 1.35 [95% CI, 1.09-1.66]) and ticagrelor (RR, 1.38 [95% CI, 1.17-1.62]) containing DAPT for 12 months had significantly higher rates, whereas high- to low-potency DAPT (RR, 0.85 [95% CI, 0.63-1.15]) had no significant risk of major bleeding. Conclusions: Aspirin and ticagrelor for 3 months, followed by aspirin and clopidogrel for the remaining duration, can be considered the optimal strategy for treating post-percutaneous coronary intervention patients with acute coronary syndrome because of a significantly reduced risk of major adverse cardiovascular events without increasing the risk of bleeding.
Net clinical benefit of dual antiplatelet therapy in elderly patients with acute coronary syndrome: A systematic review and meta-analysis

Tomohiro Fujisaki,Toshiki Kuno,Masao Iwagami,Yoshihisa Miyamoto,Hisato Takagi,Pierre Deharo,Thomas Cuisset,Alexandros Briasoulis,Sidakpal Panaich,Azeem Latib,Shun Kohsaka

DOI: https://doi.org/10.1002/ccd.30811

Abstract:Background: Contemporary dual antiplatelet therapy (DAPT) strategies, such as short-term DAPT or de-escalation of DAPT, have emerged as attractive strategies to treat patients with acute coronary syndrome (ACS). However, it remains uncertain whether they are suitable for elderly patients. Methods: PubMed, Embase, and Cochrane CENTRAL databases were searched in September 2022. Randomized controlled trials (RCTs) investigating DAPT strategies, including standard (12 months), short-term, uniform de-escalation, and guided-selection strategies for elderly patients with ACS (age ≥ 65 years) were identified, and a network meta-analysis was conducted. The primary endpoint was the net clinical benefit outcome, a composite of major adverse cardiovascular events (MACEs: cardiovascular death, myocardial infarction, or stroke) and clinically relevant bleeding (equivalent to bleeding of at least type 2 according to the Bleeding Academic Research Consortium). The secondary outcomes were MACE and major bleeding. Results: Sixteen RCTs with a combined total of 47,911 patients were included. The uniform de-escalation strategy was associated with an improved net clinical benefit compared with DAPT using potent P2Y12 inhibitors. The short-term DAPT strategy was associated with reduced risks of the primary outcome and major bleeding compared with DAPT using potent P2Y12 inhibitors, however, it was ranked as the least effective strategy for MACE compared with other DAPT strategies. Conclusions: Uniform de-escalation and short-term DAPT strategies may be advantageous for elderly patients, but need to be tailored based on individual bleeding and ischemic risks. Further RCTs of contemporary DAPT strategies specifically designed for elderly patients are warranted to confirm the findings of the present study.
Efficacy and Safety of Very Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation for Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Peng-Yu Zhong,Yao-Sheng Shang,Nan Bai,Ying Ma,Ying Niu,Zhi-Lu Wang

DOI: https://doi.org/10.3389/fcvm.2021.660360

IF: 3.6

2021-09-07

Frontiers in Cardiovascular Medicine

Abstract:Background and Objective: Dual antiplatelet therapy (DAPT) is the basis for preventing ischemic events after percutaneous coronary intervention (PCI), and DAPT for 12 months has been the standard strategy recommended by the guidelines. However, patients with acute coronary syndrome (ACS) have a higher risk of thrombosis, and the application of very short-term DAPT (1–3 months) in patients with ACS is consistently controversial. The purpose of this study is to explore the efficacy and safety of DAPT for 1–3 months in patients with ACS who were implanted with drug-eluting stents (DES). Methods: We conducted a systematic review and meta-analysis of randomized controlled trials that compared the very short-term (3 months or less) with long-term (12 months or more) DAPT in patients with ACS after PCI. The randomized controlled trials were included by searching PubMed, EMBASE, and Cochrane Library database. The relative risk (RR) and 95% CIs for endpoint events were calculated by the fixed effects model, and trial sequential analysis was applied to calculate the anticipated sample size and assess the results. Result: A total of eight randomized controlled trials with 16,492 patients who met the inclusion criteria were conducted. There were no significant statistic differences in myocardial infarction (RR 1.05, 0.82–1.35, P = 0.68), stents thrombosis (RR 1.32, 0.85–2.07, P = 0.22), all-cause death (RR 0.87, 0.66–1.13, P = 0.29), and target vessel revascularization (RR 0.93, 0.76–1.13, P = 0.47). However, there were significant differences in major bleeding (RR 0.60, 0.50–0.73, P < 0.00001) and the net adverse cardiac and cerebrovascular events (RR 0.84, 0.74–0.95, P = 0.007). Conclusions: The strategy of DAPT for 1–3 months not only has a significant effect in patients with ACS who were implanted with DES but also reduces the risk of major bleeding. The scheme of short-term DAPT followed by P2Y 12 receptor inhibitor monotherapy is especially beneficial for patients with ACS. The results of this systematic review and meta-analysis are based on the application of new generation DES and new oral antiplatelet drugs in patients with ACS, which are difficult to use in the general population (Registered by PROSPERO, CRD 42020210520). Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier: CRD 42020210520.

cardiac & cardiovascular systems
Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis

Safi U Khan,Maninder Singh,Shahul Valavoor,Muhammad U Khan,Ahmad N Lone,Muhammad Zia Khan,Muhammad Shahzeb Khan,Preethi Mani,Samir R Kapadia,Erin D Michos,Gregg W Stone,Ankur Kalra,Deepak L Bhatt

DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.046308

IF: 37.8

2020-10-13

Circulation

Abstract:Background: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with drug-eluting stents remains uncertain. We compared short-term (<6-month) DAPT followed by aspirin or P2Y12 inhibitor monotherapy; midterm (6-month) DAPT; 12-month DAPT; and extended-term (>12-month) DAPT after percutaneous coronary intervention with drug-eluting stents. Methods: Twenty-four randomized, controlled trials were selected using Medline, Embase, Cochrane library, and online databases through September 2019. The coprimary end points were myocardial infarction and major bleeding, which constituted the net clinical benefit. A frequentist network meta-analysis was conducted with a random-effects model. Results: In 79 073 patients, at a median follow-up of 18 months, extended-term DAPT was associated with a reduced risk of myocardial infarction in comparison with 12-month DAPT (absolute risk difference, -3.8 incident cases per 1000 person-years; relative risk, 0.68 [95% CI, 0.54-0.87]), midterm DAPT (absolute risk difference, -4.6 incident cases per 1000 person-years; relative risk, 0.61 [0.45-0.83]), and short-term DAPT followed by aspirin monotherapy (absolute risk difference, -6.1 incident cases per 1000 person-years; relative risk, 0.55 [0.37-0.83]), or P2Y12 inhibitor monotherapy (absolute risk difference, -3.7 incident cases per 1000 person-years; relative risk, 0.69 [0.51-0.95]). Conversely, extended-term DAPT was associated with a higher risk of major bleeding than all other DAPT groups. In comparison with 12-month DAPT, no significant differences in the risks of ischemic end points or major bleeding were observed with midterm or short-term DAPT followed by aspirin monotherapy, with the exception that short-term DAPT followed by P2Y12 inhibitor monotherapy was associated with a reduced risk of major bleeding. There were no significant differences with respect to mortality between the different DAPT strategies. In acute coronary syndrome, extended-term in comparison with 12-month DAPT was associated with a reduced risk of myocardial infarction without a significant increase in the risk of major bleeding. Conclusions: The present network meta-analysis suggests that, in comparison with 12-month DAPT, short-term DAPT followed by P2Y12 inhibitor monotherapy reduces major bleeding after percutaneous coronary intervention with drug-eluting stents, whereas extended-term DAPT reduces myocardial infarction at the expense of more bleeding events.
Design, synthesis, and bioactivity of novel inhibitors of E. coli aspartate transcarbamoylase.

J. Eldo,S. Heng,E. Kantrowitz

DOI: https://doi.org/10.1016/J.BMCL.2006.12.050

IF: 2.94

2007-04-01

Bioorganic & Medicinal Chemistry Letters

Abstract:
Laparoscopic Cholecystectomy for Polypoid Lesions of the Gallbladder: A Clinicopathologic Study

C. Yeh,Y. Jan,T. Chao,Miin‐Fu Chen

DOI: https://doi.org/10.1097/00129689-200106000-00005

2001-06-01

Abstract:The size and number of gallbladder polyps are used to differentiate between benign and malignant lesions before surgery and to determine whether surgery is necessary for the lesion. Since 1987, laparoscopic cholecystectomy has been widely used as the management method of choice for gallbladder lesions. The results of a clinicopathologic study of polypoid lesions of the gallbladder, based completely on laparoscopically resected gallbladder tissue, have not yet been evaluated fully. Data from 123 patients with polypoid lesions of the gallbladder treated by laparoscopic cholecystectomy were reviewed retrospectively. The gallbladders were classified into four histologic groups. Clinical features, maximal diameter, and the number of lesions were compared among the groups. The mean age of patients with adenoma and cancer was significantly greater than that of patients with cholesterol polyps and other lesions. More women than men had a neoplasm (adenoma and cancer). Patients in the neoplasm group tended to have a single lesion. The mean maximal diameter of neoplasms was significantly larger than that of lesions in the nonneoplasm group. All seven malignant lesions that were detected measured at least 1.5 cm. Univariate analysis showed that polypoid lesions of the gallbladder with neoplastic lesions correlated significantly with age, sex, size, and number of the lesions. Univariate analysis also showed that malignancy in polypoid lesions of the gallbladder correlated significantly with age, size, and number of the lesions. Multivariate logistic regression analysis showed that the age of the patient and the size of the lesion (≥1.0cm) are two independent factors in predicting neoplastic lesions in polypoid lesions of the gallbladder. The size of the lesion (≥1.5cm) is the only independent factor in predicting malignancy in the polypoid lesions of the gallbladder as shown by multivariate logistic regression analysis. Laparoscopic cholecystectomy is a safe and feasible method for gallbladder polypoid lesions. Neoplastic change in polypoid lesions of the gallbladder should be considered when a patient older than 50 years of age has a polypoid lesion larger than 1.0 cm. Cancer should be suspected when a polypoid lesion of the gallbladder is larger than 1.5 cm, and an aggressive surgical approach is warranted so that early gallbladder cancer can be detected and patients can have an increased chance of cure.
Efficacy and Safety of Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis

Yi Xu,Yimin Shen,Delong Chen,Pengfei Zhao,Jun Jiang

DOI: https://doi.org/10.1155/2021/9934535

2021-01-01

Journal of Interventional Cardiology

Abstract:Introduction. This network meta-analysis aimed to evaluate the efficacy and safety of different dual antiplatelet therapies (DAPTs) after percutaneous coronary intervention (PCI) with drug-eluting stents (DESs). Methods. Randomized controlled trials (RCTs) comparing longer-term (>12 months) DAPT (L-DAPT), 12-month DAPT (DAPT 12Mo), 6-month DAPT (DAPT 6Mo), 3-month DAPT followed by aspirin monotherapy (DAPT 3Mo + ASA), 3-month DAPT followed by a P2Y12 receptor inhibitor monotherapy (DAPT 3Mo + P2Y12), or 1-month DAPT with a P2Y12 receptor inhibitor monotherapy (DAPT 1Mo + P2Y12) were searched. Primary endpoints were all-cause mortality, cardiac death, myocardial infarction (MI), major bleeding, any bleeding, definite or probable stent thrombosis (ST), and net adverse clinical events (NACE). This Bayesian network meta-analysis was performed with the random-effects model. Results. Twenty-four RCTs (n = 81339) were included. In comparison with L-DAPT, DAPT 6Mo (OR: 0.50, 95% CI: 0.29-0.83), DAPT 3Mo + P2Y12 (OR: 0.38, 95% CI: 0.18-0.82), DAPT 3Mo + ASA (OR: 0.44, 95% CI: 0.17-0.98), and DAPT 1Mo + P2Y12 (OR: 0.45, 95% CI: 0.14-0.93) were associated with a lower risk of major bleeding. DAPT 3Mo + P2Y12 (OR: 0.58, 95% CI: 0.38-0.88) reduced the risk of any bleeding when compared with DAPT 12Mo. L-DAPT decreased the risk of MI and definite or probable stent ST when compared with DAPT 6Mo. DAPT 3Mo + P2Y12 decreased the risk of NACE in comparison with DAPT 6Mo and DAPT 12Mo. No significant difference in all-cause mortality and cardiac death was observed. In patients with acute coronary syndrome, DAPT 6Mo was comparable to DAPT 12Mo. Conclusion. Short-term (1-3 months) DAPT is noninferior to DAPT 6Mo after DESs implantation, while L-DAPT reduces MI and definite or probable ST rates. DAPT 3Mo + P2Y12 might be a reasonable trade-off in patients with high risk of bleeding accompanied by ischemia.
Duration of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome Treated With New Generation Stents: A Meta-Analysis of Randomized Controlled Trials

Wen-Jiao Zhang,Xuan Qiao,Wen-Fen Guo,Xi-Ying Liang,Yan Li,Zhi-Lu Wang

DOI: https://doi.org/10.3389/fcvm.2021.615396

IF: 3.6

2021-02-03

Frontiers in Cardiovascular Medicine

Abstract:Background and Objective: The optimum duration of dual antiplatelet therapy (DAPT) remains uncertain in patients with acute coronary syndrome treated with new generation stents. This meta-analysis was performed to investigate ischemia and bleeding outcomes with different DAPT strategies. Methods: PubMed, Embase, Cochrane and Web of science from inception to May 27, 2020, were systematically searched. Randomized controlled trials were included to compare short-term (6 months or less) with standard (12 months) DAPT in patients with acute coronary syndrome treated with new generation stents. The primary endpoints were myocardial infarction, definite or probable stent thrombosis and major bleeding. The secondary endpoints included all-cause death, cardiovascular death, stroke, target vessel revascularization and net adverse clinical events. Random effect model and fixed effect model were used to calculate the odds ratio (OR) and 95% confidence interval (CI) of each endpoint. Results: Four randomized controlled trials and seven subgroup analyses of larger randomized controlled trials, including a total of 21,344 patients with acute coronary syndrome, met our inclusion criteria. The shorter DAPT was associated with significantly lower major bleeding compared with the standard DAPT (OR 0.71, 95% CI 0.56–0.90, P = 0.005, I 2 = 25%), while without increasing the risk of myocardial infarction (OR 1.18, 0.88–1.58, P = 0.28, I 2 = 20%), definite or probable stent thrombosis (OR 1.60, 0.98–2.59, P = 0.06, I 2 = 0%). No significantly difference was observed in the risk of all-cause death (OR 0.96, 0.72–1.27, P = 0.76, I 2 = 2%), cardiovascular death (OR 0.91, 0.62–1.33, P = 0.62, I 2 = 0%), stroke (OR 0.84, 0.54–1.30, P = 0.43, I 2 = 0%), target vessel revascularization (OR 1.14, 0.84–1.55, P = 0.41, I 2 = 8%), and net adverse clinical events (OR 0.93, 0.80–1.07, P = 0.3, I 2 = 18%) between the two groups. Conclusions: In patients with acute coronary syndrome treated with new generation stents, the shorter DAPT leads to a marked reduction in the risk of major bleeding compared with the standard DAPT. This benefit is achieved without increasing the risk of mortality or ischemic outcomes. The study protocol was registered in PROSPERO (CRD42020189871).

cardiac & cardiovascular systems
De-escalation of antiplatelet therapy in patients with coronary artery disease: Time to change our strategy?

Pierre Sabouret,Luigi Spadafora,David Fischman,Waqas Ullah,Michel Zeitouni,Martha Gulati,Salvatore De Rosa,Juan Pablo Costabel,Maciej Banach,Giuseppe Biondi-Zoccai,Mattia Galli,Michael P. Savage

DOI: https://doi.org/10.1016/j.ejim.2022.12.008

IF: 7.749

2022-12-27

European Journal of Internal Medicine

Abstract:Dual antiplatelet therapy (DAPT) is the gold standard after acute coronary syndromes (ACS) or chronic coronary syndromes (CCS) undergoing percutaneous coronary intervention (PCI). Because local and systemic ischemic complications can occur particularly in the early phase (i.e. 1–3 months) after ACS or PCI, the synergistic platelet inhibition of aspirin and a P2Y 12 inhibitor is of the utmost importance in this early phase. Moreover, the use of the more potent P2Y 12 inhibitors prasugrel and ticagrelor have shown to further reduce the incidence of ischemic events compared to clopidogrel after an ACS. On the other hand, prolonged and potent antiplatelet therapy are inevitably associated with increased bleeding, which unlike thrombotic risk, tends to be stable over time and may outweigh the benefit of reducing ischemic events in these patients. The duration and composition of antiplatelet therapy remains a topic of debate in cardiology due to competing ischemic and bleeding risks, with guidelines and recommendations considerably evolving in the past years. An emerging strategy, called "de-escalation", consisting in the administration of a less intense antithrombotic therapy after a short course of standard DAPT, has shown to reduce bleeding without any trade-off in ischemic events. De-escalation may be achieved with different antithrombotic strategies and can be either unguided or guided by platelet function or genetic testing. The aim of this review is to summarize the evidence and provide practical recommendations on the use of different de-escalation strategies in patients with ACS and CCS.

medicine, general & internal
DNA replication in cell-free extracts from Xenopus laevis.

G. H. Leno,R. Laskey

DOI: https://doi.org/10.1016/S0091-679X(08)60297-6

Methods in Cell Biology

Abstract:
Dual antiplatelet therapy for ischemic stroke with intracranial arterial stenosis: a systematic review and meta-analysis

Haifeng Shao,Song He,Ping Ni,Danni Zheng,Nengwei Yu,Qiao Chen,Xinyi Leng,Yan Lin,Suping Li,Jie Yang,Xia Wang

DOI: https://doi.org/10.3389/fneur.2024.1411669

IF: 3.4

2024-06-11

Frontiers in Neurology

Abstract:Background: The safety and efficacy of dual antiplatelet therapy (DAPT) in ischemic stroke patients with intracranial artery stenosis (ICAS) remain contentious. Aims: This study evaluates DAPT's effectiveness and safety for these patients. Methods: This review was reported following PRISMA 2020 guidelines. A comprehensive search was conducted in PubMed, Embase, Cochrane Library, ClinicalTrials.gov, CNKI, WanFang, VIP, and SinoMed up to June 20, 2023, for randomized controlled trials comparing efficacy and safety of DAPT against single antiplatelet therapy (SAPT) in ischemic stroke patients with ICAS. The primary outcome was a composite of ischemic and bleeding events. Secondary outcomes included stroke (cerebral infarction and hemorrhage), ischemic events, and cerebral infarction. Safety outcomes assessed were bleeding events, cerebral hemorrhage, and mortality. Risk ratios (RRs) with 95% confidence intervals (CIs) were synthesized using Review Manager 5.4. Results: Analysis of 21 randomized controlled trials involving 3,591 patients revealed that DAPT significantly lowered the rate of ischemic and bleeding events (RR = 0.52; 95% CI: 0.46–0.59, p < 0.001) and recurrent stroke (RR = 0.37; 95% CI: 0.30–0.44, p < 0.001) compared to SAPT. There was no significant increase in bleeding events (RR = 1.34; 95% CI: 0.97–1.85, p = 0.07) or cerebral hemorrhage (RR = 0.47; 95% CI: 0.17–1.31, p = 0.15). Conclusion: DAPT proveed to be effective and safe for ischemic stroke patients with ICAS and significantly reduced stroke and the composite endpoint of ischemic and bleeding events without elevating bleeding risks.

neurosciences,clinical neurology
P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack.

Zi-Xiao Li,Yunyun Xiong,Hong-Qiu Gu,Marc Fisher,Ying Xian,S. Claiborne Johnston,Yong-Jun Wang

DOI: https://doi.org/10.1161/strokeaha.120.033040

IF: 10.17

2021-05-29

Stroke

Abstract:We performed a systemic review and meta-analysis to elucidate the effectiveness and safety of dual antiplatelet (DAPT) therapy with P2Y12 inhibitors (clopidogrel/ticagrelor) and aspirin versus aspirin monotherapy in patients with mild ischemic stroke or high-risk transient ischemic attack. Following Preferred Reported Items for Systematic Review and Meta-Analysis standards for meta-analyses, Medline, Embase, Cochrane Central Register of Controlled Trials, and the Cochrane Library were searched for randomized controlled trials that included patients with a diagnosis of an acute mild ischemic stroke or high-risk transient ischemic attack, intervention of DAPT therapy with clopidogrel/ticagrelor and aspirin versus aspirin alone from January 2012 to July 2020. The outcomes included subsequent stroke, all-cause mortality, cardiovascular death, hemorrhage (mild, moderate, or severe), and myocardial infarction. A DerSimonian-Laird random-effects model was used to estimate pooled risk ratio (RR) and corresponding 95% CI in R package meta. We assessed the heterogeneity of data across studies with use of the Cochran Q statistic and I 2 test. Four eligible trials involving 21 493 participants were included in the meta-analysis. DAPT therapy started within 24 hours of symptom onset reduced the risk of stroke recurrence by 24% (RR, 0.76 [95% CI, 0.68–0.83], I 2 =0%) but was not associated with a change in all-cause mortality (RR, 1.30 [95% CI, 0.90–1.89], I 2 =0%), cardiovascular death (RR, 1.34 [95% CI, 0.56–3.17], I 2 =0%), mild bleeding (RR, 1.25 [95% CI, 0.37–4.29], I 2 =94%), or myocardial infarction (RR, 1.45 [95% CI, 0.62–3.39], I 2 =0%). However, DAPT was associated with an increased risk of severe or moderate bleeding (RR, 2.17 [95% CI, 1.16–4.08], I 2 =41%); further sensitivity tests found that the association was limited to trials with DAPT treatment duration over 21 days (RR, 2.86 [95% CI, 1.75–4.67], I 2 =0%) or ticagrelor (RR, 2.17 [95% CI, 1.16–4.08], I 2 =37%) but not within 21 days or clopidogrel. In patients with noncardioembolic mild stroke or high-risk transient ischemic attack, DAPT with aspirin and clopidogrel/ticagrelor is more effective than aspirin alone for recurrent stroke prevention with a small absolute increase in the risk of severe or moderate bleeding.

peripheral vascular disease,clinical neurology
Optimizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

Safi U. Khan,Neal S. Kleiman

DOI: https://doi.org/10.1001/jamanetworkopen.2024.6951

2024-03-29

JAMA Network Open

Abstract:The observation by Colombo and colleagues 1 that dual antiplatelet therapy (DAPT), comprising aspirin and a P2Y12 antagonist, offers optimal antithrombotic protection following intracoronary stent implantation catalyzed the widespread adoption of intracoronary stents. Historically, stent thrombosis, a catastrophic event, was a concern primarily in the immediate aftermath of stent placement. However, the observation of stent thromboses occurring beyond 30 days in patients receiving first-generation, drug-eluting stents underscored the persistent nature of this risk. Consequently, the ideal DAPT duration has become the focal point of innumerable clinical trials and meta-analyses, even as stent thrombosis has substantially declined with modern stent platforms and intravascular imaging techniques. The challenge lies in balancing the ischemic risk associated with shorter DAPT duration against the bleeding risk entailed by extended therapy. While intuitively one might expect a bleeding event to be less catastrophic than stent thrombosis or myocardial infarction, studies 2 have shown otherwise. This dilemma is particularly accentuated in older adults, whose complex health profiles amplify their susceptibility to both bleeding and ischemic complications. Park and colleagues 3 present a network meta-analysis (NMA) evaluating various DAPT durations following percutaneous coronary interventions (PCI) in older adults. Among 14 trials, including 19 102 participants aged 65 years or older, they found no significant differences in major adverse cardiovascular events (MACE) or net adverse clinical events (NACE), as defined variably in each trial, across 1-, 3-, 6-, or 12-month DAPT. 3 The study showed that short-term DAPT strategies (ie, 3- vs 6-month DAPT, 3- vs 12-month DAPT, and 1- vs 6-month DAPT) were associated with a significant reduction in bleeding risk, suggesting that short-term DAPT may offer a safer option for older adults without compromising efficacy against MACE or NACE. 3 While evaluating the ischemic and bleeding risk is fundamentally a bivariate process, NACE, which includes bleeding and ischemic events, was introduced as a unidimensional metric to quantify the overall risk-benefit profile of antithrombotic therapies. In this NMA, 3 given that 1- to 3-month DAPT compared with 6- to 12-month DAPT was associated with reduced bleeding risk without increasing ischemic risk, one would anticipate a corresponding reduction in NACE rather than a null effect. Additionally, the observation that 1-month compared with 6-month DAPT, but not 12-month DAPT, reduced bleeding prompts scrutiny of study design and evidence before clinical application. Using indirect evidence in an NMA requires the assumption that compared trials share similarities in patient characteristics, treatment protocol, and outcome measures. However, verifying this assumption is complicated by trial-level heterogeneity, including differences in antiplatelet therapies after DAPT deescalation, baseline risks for bleeding and ischemic events, and outcome definitions. For instance, the SMART-CHOICE trial 4 indicated that clopidogrel after 3-month DAPT in a broad patient population was effective in reducing bleeding without compromising MACE. Conversely, the TWILIGHT trial 5 found that ticagrelor monotherapy following 3-month DAPT vs 12-month DAPT decreased bleeding without elevating ischemic risk in high-risk patients. The diversity in antiplatelet therapy among trials, involving 3 different P2Y12 antagonists and different doses of aspirin, further complicates the analysis. 3 Moreover, several additional issues pose challenges when translating these findings into clinical practice. For instance, aligning events of comparable clinical significance on both sides of the calculus is imperative for a precise assessment of the risk-benefit ratio. The definitions of NACE and MACE in each trial incorporated events of varying clinical significance, ranging from all-cause mortality to less critical events like target vessel revascularization. 3 Additionally, only 5 trials included stent thrombosis in composite outcomes, and inconsistencies exist in classifying bleeding risk across trials. The distinct relative risk reductions offered by different DAPT regimens for various end points further emphasize the necessity of analyzing treatment effects on individual end points. Nonetheless, acknowledging these limitations, what does this study 3 add to the evidence? Consistent with recent evidence in other populations, this NMA 3 supports the notion that short-term DAPT is likely the ideal strategy to minimize the bleeding risk without compromising the protection against ischemic events in older adults. However, a universal DAPT duration and selection approach may not apply to all patient scenarios. Lim -Abstract Truncated-

medicine, general & internal
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis

Diana A. Gorog,Jose Luis Ferreiro,Ingo Ahrens,Junya Ako,Tobias Geisler,Sigrun Halvorsen,Kurt Huber,Young-Hoon Jeong,Eliano P. Navarese,Andrea Rubboli,Dirk Sibbing,Jolanta M. Siller-Matula,Robert F. Storey,Jack W. C. Tan,Jurrien M. ten Berg,Marco Valgimigli,Christophe Vandenbriele,Gregory Y. H. Lip

DOI: https://doi.org/10.1038/s41569-023-00901-2

IF: 49.421

2023-07-21

Nature Reviews Cardiology

Abstract:Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y purinoceptor 12 (P2Y 12 ) inhibitor (prasugrel or ticagrelor) for 12 months. Although this approach reduces ischaemic risk, patients are exposed to a substantial risk of bleeding. Strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y 12 inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT duration. Either strategy requires assessment of the ischaemic and bleeding risks of each individual. De-escalation of DAPT intensity can reduce bleeding without increasing ischaemic events and can be guided by platelet function testing or genotyping. Abbreviation of DAPT duration after 1–6 months, followed by monotherapy with aspirin or a P2Y 12 inhibitor, reduces bleeding without an increase in ischaemic events in patients at high bleeding risk, particularly those without high ischaemic risk. However, these two strategies have not yet been compared in a head-to-head clinical trial. In this Consensus Statement, we summarize the evidence base for these treatment approaches, provide guidance on the assessment of ischaemic and bleeding risks, and provide consensus statements from an international panel of experts to help clinicians to optimize these DAPT approaches for individual patients to improve outcomes.

cardiac & cardiovascular systems

Answers to the antiphospholipid-antibody syndrome?

Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis

Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis

Comparing dual antiplatelet therapy strategies post-acute coronary syndrome: network meta-analysis

Comparison of Unguided De-Escalation Versus Guided Selection of Dual Antiplatelet Therapy After Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis

SHORT-TERM DUAL ANTIPLATELET THERAPY AFTER DRUG-ELUTING STENTING IN PATIENTS WITH ACUTE CORONARY SYNDROMES: A BAYESIAN NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Acute lymphocytic leukemia presenting as masquerade syndrome.

Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis

Net clinical benefit of dual antiplatelet therapy in elderly patients with acute coronary syndrome: A systematic review and meta-analysis

Efficacy and Safety of Very Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation for Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis

Design, synthesis, and bioactivity of novel inhibitors of E. coli aspartate transcarbamoylase.

Laparoscopic Cholecystectomy for Polypoid Lesions of the Gallbladder: A Clinicopathologic Study

Efficacy and Safety of Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis

Duration of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome Treated With New Generation Stents: A Meta-Analysis of Randomized Controlled Trials

De-escalation of antiplatelet therapy in patients with coronary artery disease: Time to change our strategy?

DNA replication in cell-free extracts from Xenopus laevis.

Dual antiplatelet therapy for ischemic stroke with intracranial arterial stenosis: a systematic review and meta-analysis

P2Y12 Inhibitors Plus Aspirin Versus Aspirin Alone in Patients With Minor Stroke or High-Risk Transient Ischemic Attack.

Optimizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis